Click here to view online. Add this email to your safelist.
Brilinta significantly reduced the rate of the composite of stroke and death in patients who had an acute ischaemic stroke or transient ischaemic attack in the Phase III THALES trial
16 July 2020
Detailed results from the positive Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate of the primary composite endpoint of stroke and death by 17% (HR 0.83 [95% CI 0.71, 0.96], p=0.02), compared to aspirin alone in patients who had an acute ischemic stroke or transient ischemic attack (TIA).
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
